NEOPLASM METASTASIS

This early-stage study tests a new drug, LOXO-435, in people with advanced solid tumors, especially urinary tract cancers that have a specific change in the FGFR3 gene. The main goals are to find the best dose and check for safety and side effects. About 535 participants will tak…

This study tests a new drug called LY4257496 that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, prostate, colorectal, or endometrial cancer that has spread. The goal is to see if the drug is safe and can shrink …

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments helps people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the new drug combo or standard therapy. Th…

This study tests a new combination of the drug cadonilimab plus chemotherapy and radiation for people whose endometrial cancer has come back or spread to a few other spots. About 30 participants will receive the treatment and be monitored for tumor shrinkage, survival, and side e…

This early-phase study tests a new three-drug combination (zanzalintinib, pembrolizumab, and cetuximab) in adults with recurrent or metastatic head and neck cancer that cannot be cured by local treatments. The main goal is to find the safest dose and check for early signs of tumo…

This study tests whether adding a new drug called vepugratinib to two standard cancer treatments (enfortumab vedotin and pembrolizumab) helps adults with advanced or spreading bladder cancer that has a specific FGFR3 gene change. About 450 participants will receive either the new…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+/HER2- breast cancer that has a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The g…

This study tests a new drug, Sofetabart Mipitecan, for people with ovarian, fallopian tube, or peritoneal cancer. Part A includes those whose cancer no longer responds to platinum chemotherapy, and Part B includes those whose cancer still responds. The goal is to see if the new d…

This study is following 3000 men with prostate cancer to understand why the disease progresses differently in different people. Researchers are looking at genetics, lifestyle, and medical history to find factors that predict recurrence or spread. The goal is to improve treatment …

This study follows 800 adults with advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers will track how long patients stay on treatment, their quality of life, and an…